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Abstract
Background: Mounting evidence supports a significant role of inflammation in Parkinson’s disease (PD)
pathophysiology, with several inflammatory pathways being suggested as playing a role in the dopaminergic
degeneration seen in humans and animal models of the disease. These include tumor necrosis factor,
prostaglandins and oxidative-related stress components. However, the role of innate immunity has not been
established in PD.
Methods: Based on the fact that the myeloid differentiation primary response gene (88) (MyD88) is the most
common adaptor protein implicated in toll-like receptor (TLR) signaling, critical in the innate immune response, we
undertook a study to investigate the potential contribution of this specific pathway to MPTP-induced brain
dopaminergic degeneration using MyD88 knock out mice (MyD88-/-), following our observations that the MyD88-
dependent pathway was critical for MPTP dopaminergic toxicity in the enteric nervous system. Post-mortem
analyses assessing nigrostriatal dopaminergic degeneration and inflammation were performed using HPLC, western
blots, autoradiography and immunofluorescence.
Results: Our results demonstrate that MyD88-/- mice are as vulnerable to MPTP-induced dopamine and DOPAC
striatal depletion as wild type mice. Furthermore, MyD88-/- mice show similar striatal dopamine transporter and
tyrosine hydroxylase loss, as well as dopaminergic cell loss in the substantia nigra pars compacta in response to
MPTP. To evaluate the extent of the inflammatory response created by the MPTP regimen utilized, we further
performed bioluminescence imaging using TLR2-luc/gfp transgenic mice and microglial density analysis, which
revealed a modest brain microglial response following MPTP. This was accompanied by a significant astrocytic
reaction in the striatum, which was of similar magnitude both in wild type and MyD88-/- mice.
Conclusions: Our results suggest that subacute MPTP-induced dopaminergic degeneration observed in the central
nervous system is MyD88-independent, in contrast to our recent observations that this pathway, in the same
cohort of animals, is critical in the loss of dopaminergic neurons in the enteric nervous system.
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Background
Parkinson’s disease (PD) is a neurodegenerative disorder
for which the mechanisms of neuronal degeneration are
currently unclear. However, sustained neuroinflamma-
tion has been suggested to contribute to the pathophy-
siology of several disorders of the central nervous
system (CNS), including PD. Indeed, evidence from a
number of human post-mortem studies has revealed the
presence of chronic neuroinflammation in PD patients
[1,2]. Elevated levels of various inflammatory mediators
such as tumor necrosis factor alpha (TNFa), interleukin
(IL)-1b,I L - 2 ,I L - 6 ,i n t e r f e r o ng, inducible nitric oxide
synthase (iNOS) and cyxlooxygenase-2 (COX-2),
together with the presence of activated microglia and
astrocytes, have all been observed in the brain of PD
patients [3-15]. Furthermore, a reduced risk of develop-
ing the disease has been reported in individuals taking
non-steroidal anti-inflammatory drugs [16-18].
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dopaminergic neurodegenerative processes in various
animal models of PD. In the 6-hydroxydopamine (6-
OHDA) model of PD, microglial activation [19-24] can
be partially inhibited by minocycline, and this prevents
neuronal degeneration [25]. Lipopolysaccharide (LPS)
has also been shown to be a potent stimulator of glial
cells in the CNS and to provoke the release of various
cytokines and free radicals, leading to dopaminergic
neuronal loss in the substantia nigra (SNpc) when
injected intra-nigrally [24,26,27]. In the 1-methyl-4-phe-
nyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model
of PD, the activation of microglia in both the striatum
and SNpc is well documented [28,29]. However, which
specific inflammatory pathways are critically activated in
response to MPTP is unresolved. For example, mice
lacking both genes encoding for TNF receptors are
completely protected against the decrease in striatal tyr-
osine hydroxylase (TH) and dopamine content following
a single subcutaneous MPTP injection [30], seemingly
consequential to the absence of microglial activation in
t h e s ek n o c ko u t( K O )m i c e[ 3 1 ] .T h eT N Fp a t h w a yi s
activated by the release of the pro-inflammatory cyto-
kine TNFa, which is associated with the acute phase of
inflammation in reaction to MPTP [30] leading to the
activation of Nuclear factor kappa B (NFB), Mitogen-
activated protein kinase (MAPK) or induced apoptosis.
However, other inflammatory mediators have also been
suggested to play a role in MPTP-induced dopaminergic
degeneration, albeit not to the same extent. Mice
depleted in gp91phox and iNOS are partially protected
against MPTP-induced acute neurodegeneration [32-36].
Gp91phox is part of the membrane bound complex
NADPH-oxidase which, upon activation, generates
superoxide radicals [37]. iNOS is an enzyme that cata-
lyzes the production of nitric oxide in response to pro-
inflammatory cytokine production, which has been sug-
gested to be involved in PD [38]. These two components
are parts of the oxidative related stress pathways, which
involve reactive oxygen species (ROS) production, contri-
buting to tissue damage and death. Finally, mice depleted
in COX-2 show incomplete nigral dopaminergic protec-
tion against MPTP-induced damages [39,40]. COX-2 is a
rate-limiting enzyme which can be produced in response
to an increase in pro-inflammatory cytokines and is
responsible for the conversion of arachidonic acid into
prostaglandins [41]. These pathways take also part in the
innate immune response and can directly or indirectly
activate the MAPK, p38 and NFBp a t h w a y s .H o w e v e r ,
they differ from the Myeloid differentiation primary
response gene (88) (MyD88)-dependant pathway in that
toll-like receptors (TLRs) have a wider range of specific
pathogenous and endogenous ligands.
MyD88 is an adaptor protein required by all TLRs,
with the possible exception of TLR3 [42]. TLRs are
pattern recognition receptors and contribute to CNS
neurotoxicity largely by initiating and regulating
inflammatory activities [43-45]. In addition, the
immune response to infectious and noninfectious
pathologies in the CNS is prompted or amplified by
the activation of certain TLRs by endogenous ligands
[46,47]. TLR-induced signaling also activates the adap-
tive immune system, as testified by the secretion of
type I interferon, which enhances dendritic cell
maturation, activation of natural killer cells, antibody
production, and differentiation of virus-specific cyto-
toxic T lymphocytes [44]. Furthermore, MyD88 is a
TIR-domain-containing adaptor protein of the IL-1
receptor family [48]. The activation of the MyD88-
dependent pathway leads to the production of different
pro-inflammatory mediators via NFBo rp 3 8a n dJ u n -
N-terminal kinase (JNK) [49], while in contrast, the
TRIF-dependent pathway, the most studied of MyD88-
independent pathways, drives the induction of type I
interferon as well as inflammatory cytokines and
trophic factors [42].
While little is known about the role of MyD88 in
neurodegenerative diseases, there is some evidence
that it may be important. MyD88 present in bone-
marrow hematopoietic cells has been demonstrated to
be neuroprotective in an animal model of amyo-
trophic lateral sclerosis [50], although bone-marrow-
derived cells lacking MyD88 improve Alzheimer’sd i s -
ease-like pathology in two different mouse models of
the disease [51]. Observations on the possible involve-
ment of the innate immune system in PD have only
recently emerged. Increased expression of TLR4 and
its co-receptor CD14 has been reported 14 days fol-
lowing a single MPTP injection in mice [52], along
with induction of TLR3, TLR4, TLR9 and MyD88 fol-
lowing an acute MPTP treatment [53]. Furthermore,
TLR4 has been shown to promote the clearance of a-
synuclein and thus dopaminergic neuronal survival in
a mouse model of multiple system atrophy character-
ized by oligodendroglial a-synuclein overexpression
[54].
We have recently reported that the MyD88-dependent
pathway is critical for dopaminergic neuronal degenera-
tion induced by the neurotoxin MPTP in the enteric
nervous system (ENS) of the mouse [55]. In the CNS,
MPTP administration has repeatedly been used as a
model for PD [56-58] and given our findings for the
role of the MyD88-dependent pathway in the ENS [55],
we have now sought to look at the contribution of this
pathway to CNS dopaminergic cell loss using the same
cohort of mice.
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Animals and parkinsonian model
MyD88-deficient (MyD88-/-) mice exhibit a deficiency
in T cell proliferation, induction of acute phase proteins
and inflammatory cytokines in response to IL-1, along
with the absence of interferon-g production and natural
killer cell activity in response to IL-18 [59]. They have
also previously been shown to be unresponsive to LPS, a
ligand of TLR4 [60]. Here, we used the MyD88-/-
mouse because this protein is a paramount component
of the innate immune response [42].
All animals (25-35 g) were acclimatized to standard
laboratory conditions in a controlled-temperature envir-
onment maintained under a 12 h light/dark cycle with
free access to food and water. All animal experiments
were performed in accordance with the Canadian Guide
for the Care and Use of Laboratory animals and all pro-
cedures were approved by the Institutional Animal Care
Committee of Laval University. Adult C57BL/6 wild
type (WT) and MyD88-/- mice maintained on a C57BL/
6 background (n = 7-8 per group and time points)
received seven intraperitoneal (i.p.) injections of freshly
diluted MPTP-HCl (20 mg/kg; Sigma, St. Louis, MO,
USA) dissolved in saline 0.9%. MPTP was administered
in a subacute manner, twice a day at 12-hour (h) inter-
vals on the first two days and once a day for three sub-
sequent days [61]. Remaining animals received i.p.
vehicle injections instead of MPTP administration. Mice
were sacrificed 3 h and 14 days following the last MPTP
injection, as previously described in our ENS study on
this cohort of animals [55].
Transgenic TLR2-luc/gfp mice enabled us to study in
vivo the microglial activation/TLR2 response to subacute
MPTP treatment. These mice, maintained on a C57BL/6
background, bear a bicistronic DNA construct (reporter
genes luciferase (luc) and green fluorescent protein
(gfp)), which is under the transcriptional control of the
murine TLR2 promoter [62]. Transgenic animals were
identified by PCR detection of luciferase as previously
described [62] and maintained as a heterozygous geno-
type. An additional group of C57BL/6 mice were also
subjected to an identical MPTP and saline regimen and
sacrificed 24 h, 7 days and 14 days following the end of
the MPTP treatment. These animals were used for
microglial density analysis and evaluation of striatal
GFAP protein levels.
In vivo bioluminescence imaging
TLR2-luc/gfp mice were scanned 1 h following MPTP
injections (the 1
st to 4
th and 6
th) ,a sw e l la s3h ,2 4h
and 7 days following the last injection. Animals were all
sacrificed 14 days following the end of the MPTP treat-
ment. The TLR2-luc/gfp mice were strictly used for
imaging purposes. Images were collected using an IVIS
®
200 Imaging System (CaliperLS-Xenogen, Alameda, CA,
USA). Twenty minutes (min) prior to imaging sessions,
mice were administered a luciferase substrate D-lucifer-
ine dissolved in saline 0.9% (150 mg/kg) (CaliperLS-
Xenogen) via the i.p. route. Mice were anesthetized with
2% isoflurane in 100% O2 at a flow rate of 2 L/min and
placed in a heated, light-tight imaging chamber. Images
were collected according to a previously published pro-
tocol [62]. Briefly, bioluminescence imaging was per-
formed using a high-sensitivity CCD camera with
wavelengths ranging from 300 to 600 nm with different
fields of views and an f/1 lens aperture. Exposure time
for imaging was 2 min, bioluminescence emission was
normalized and light output was quantified as the total
number of photons emitted per second with the use of
Living Image 4.0 acquisition and imaging software (Cali-
perLS-Xenogen).
Tissue preparation for post-mortem analyses
Animals were sacrificed under deep anesthesia with
ketamine/xylazine and perfused using a standard trans-
cardiac infusion of PBS 1× (BioShop, Burlington, ON,
Canada) containing protease (Sigma, St. Louis, MO,
USA) and phosphatase inhibitors (sodium pyropho-
sphate 1 mM and 50 mM sodium fluoride). Brains were
collected and either post-fixed in a solution containing
4% paraformaldehyde (PFA; pH 7.4) in PBS for 48 h and
subsequently cryoprotected using a 20% sucrose solution
o rs n a p - f r o z e ni n2 - m e t h y l - b u t a n ea n dt h e ns t o r e da t
-80°C. Post-fixed coronal brain sections of 25 μm thick-
ness were cut using a freezing microtome (Leica Micro-
systems, Montreal, QC, Canada). Samples of the
striatum were extracted for high performance liquid
chromatography (HPLC) and western blot analyses,
along with mesencephalon samples for the latter
method. Coronal brain sections (12 μm) were cut on a
cryostat and stored at -80°C for histological analyses.
Dopamine and DOPAC HPLC quantification
Dopamine and 3, 4-dihydroxyphenylacetic acid
(DOPAC) were measured by HPLC with electrochemical
detection according to a previously published protocol
[63] in WT and MyD88-/- mice sacrificed 14 days fol-
lowing the end of MPTP treatment. Extracts of striata
were collected, and 200 μl of perchloric acid (0.1 N;
Mallinckrodt Baker, Inc. Phillipsburg, NJ, USA) was
added to generate a supernatant. Fifty μl of supernatant
was then directly injected into the HPLC consisting of a
717 plus autosampler automatic injector, a 1525 binary
pump equipped with an Atlantis dC18 (3 μl) column, a
2465 electrochemical detector, and a glassy carbon elec-
trode (Waters Limited, Lachine, QC, Canada). The elec-
trochemical potential was set at 10 nA. The mobile
phase consisted of 47.8 mM NaH2PO4, 0.9 mM sodium
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USA), 0.4 mM EDTA, 2 mM NaCl and 8% MeOH
(Mallinckrodt Baker, Inc. Phillipsburg, NJ, USA) at pH
2.9 and delivered at 0.8 ml/min. Peaks were identified
u s i n gB r e e z es o f t w a r e( W a t e rs limited, Lachine, QC,
Canada). HPLC quantifications were normalized to pro-
tein concentrations. Protein measurements were deter-
mined with a bicinchoninic acid (BCA) protein assay kit
(Pierce, Rockford, IL, USA) as described by the manu-
facturer’s protocol.
Histology and microscopy
Sections were processed for immunohistochemistry to
visualize TH+ neurons of the SNpc. Sections were
incubated for 30 min in 3% H2O2 and blocked in a
0.1 M PBS solution containing 0.1% Triton X-100
(Sigma, St. Louis, MO, USA) and 5% normal goat
serum (NGS; Wisent, QC, Canada) for 30 min. After
o v e r n i g h ti n c u b a t i o na t4 ° Cw i t har a b b i ta n t i - T H( 1 : 5
000; Pel-freeze, Rogers, AR, USA), sections were
washed in PBS and incubated for 1 h at room tem-
perature (RT) in a PBS solution containing biotiny-
lated goat anti-rabbit IgG (1:1 500; Vector
Laboratories, Burlington, ON, Canada). After further
washing in PBS, the sections were placed in a solution
containing ABC (Elite kit; Vector Laboratories, Bur-
lington, ON, Canada) for 1 h at RT. The bound per-
oxidase was revealed with nickel intensified DAB as
the chromogen (Sigma-Aldrich, St. Louis, MO, USA)
and 0.01% hydrogen peroxide in 0.05 M Tris (pH 7.6)
at RT. The reaction was stopped after approximately 5
min by extensive washing in PBS. Following the Ni-
DAB reaction, sections were dehydrated and cover-
slipped. Photomicrographs were taken with a Micro-
fire 1.0 camera (Optronics, Goleta, CA) linked to an
E800 Nikon microscope (Nikon Inc., Québec, QC,
Canada) using the imaging software Picture Frame
(Microbrightfield, Colchester, VT, USA) and prepared
for illustration in Adobe Photoshop CS5 12.0 x32 and
Adobe Illustrator CS5 15.0.0.
For microglial density assessment, immunofluores-
cence of nigral sections using an antibody against iba1
was performed. After overnight incubation at 4°C with
a rabbit anti-iba1 (ionized calcium binding adaptor
molecule 1; 1:1 000; Waco Pure Chemicals Industries,
Richmond, VA, USA), sections were washed in PBS
and incubated for 2 h at RT in a PBS solution contain-
ing the secondary antibody, goat Alexa Fluor 488-con-
jugated anti-rabbit (1:1 000; Invitrogen, Eugene, OR,
USA). Following three washes in PBS, sections were
placed in a solution containing DAPI (0.022%) for 7
min at RT and washed again twice before being
mounted on slides and coverslipped using fluoromount
(Southern Biotech, AL, USA) sealed with nail polish.
Photomicrographs were taken using a fluorescent light
microscope (Olympus Provis AX70, Melville, NY,
USA).
Stereological quantification
The density of TH+ neurons and iba1+ microglia was
assessed in the SNpc. TH measurements were per-
formed under bright-field illumination, while iba1+ cell
counting was performed using fluorescent light. Four
sections of a 4-section (time course of inflammatory
events protocol) or 5-section series (protocol using
MyD88-/- mice) [64] were sampled using the Stereo
investigator software (MicroBrightfield, Colchester, VT,
USA) attached to an E800 Nikon microscope (Nikon
Canada Inc, Mississauga, ON, Canada). The optical
fractionator method [65] was used for cell counting
and volume measurements through a 20× objective
with the following counting parameters: distance
between counting frames (150 μm × 150 μm), counting
f r a m es i z e( 1 0 0μm) and guard zone thickness (2 μm).
Cells were counted only if they did not intersect for-
bidden lines.
[
125I]-RTI-121 autoradiography
Dopamine transporter (DAT) binding was evaluated
with [
125I]-RTI-121 [3b-(4-[
125I]-iodophenyl) tropane-
2b-carboxylic acid isopropylester] (NEN-DuPont, Bos-
ton, MA, USA; 2200 Ci/mmol) at 14 days following the
last MPTP injection according to a previously published
protocol [66]. Briefly, cryostat tissue sections were pre-
incubated at RT for 30 min in a phosphate buffer (10.1
mM NaHPO4,1 . 8m MK H 2PO4,1 3 7m MN a C l ,a n d2
mM KCl pH 7.4). Dried sections were subsequently
incubated for 90 min at RT with 20 pM [
125I]-RTI-121.
Nonspecific binding was determined in the presence of
10 μM mazindol (Novartis, Basel, Switzerland). Follow-
ing two 20 min washes in phosphate buffer, sections
were briefly rinsed in ice-cold distilled water. When dry,
sections were apposed against BiomaxMR radioactive
sensitive films for 24 h.
Quantification of [
125I]-RTI-121 autoradiography
Digitized images of the striatum were obtained with a
CCD camera model XC-77 (Sony Electronics Inc., New
York, NY, USA) equipped with a 60 mm f/2.8 D magni-
fication lens (Nikon Canada Inc., Mississauga, ON,
Canada). The optical density of [
125I]-RTI-121 specific
binding was analyzed on a MacIntosh computer using
Image J software (NIH, http://rsbweb.nih.gov/ij/). The
average labeling for each area was calculated from three
adjacent brain sections of a 1/20 series of the same ani-
mal at the level of the striatum (AP levels: 1.25 mm to
0.53 mm) [64]. Non-specific binding was subtracted
from every measurement.
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Samples were homogenized in 8 volumes of lysis buffer
(150 mM NaCl, 10 mM NaH2PO4,1 %t r i t o nX - 1 0 0 ,
0.5% SDS, and 0.5% deoxycholate) containing a cocktail
of protease and phosphatase inhibitors. Samples were
sonicated (3 × 10 sec) and centrifuged at 100 000 × g
for 20 min at 4°C. The supernatant was collected and
stored at -80°C. The protein concentration was deter-
mined using a BCA protein assay kit with bovine serum
albumin as the standard. Fifteen μg of total protein per
sample was added to laemmli loading buffer and heated
to 95°C for 5 min. Samples were then loaded and sub-
jected to sodium dodecyl sulfate-polyacrylamide (8%) gel
electrophoresis. Proteins were electroblotted onto 0.45
μm PVDF membranes (Immobilon, Millipore, MA,
USA) and blocked in 5% nonfat dry milk and 1% BSA
in PBS for 1 h. Membranes were immunoblotted with
mouse anti-GFAP (1:10 000; Sigma, St. Louis, MO,
USA), rabbit anti-TH (1:5 000; Pel-freeze, Rogers, AR,
USA) or mouse anti-b-actin (1:10 000; Applied Biologi-
cal Materials Inc., Richmond, BC, Canada) and HRP-
conjugated goat anti-mouse and anti-rabbit secondary
antibodies (1:100 000; Jackson Immunoresearch Inc.,
West Grove, PA, USA) followed by chemiluminescence
reagents (KPL, Mandel scientific Inc., Guelph, ON,
Canada). Band intensities were quantified using a
KODAK Image Station 4000 Digital Imaging System
(Molecular Imaging Software version 4.0.5f7, KODAK,
New Haven, CT) or a ImageQuant LAS 4000 lumines-
cent image analyzer (GE Healthcare, Piscataway, NJ,
USA).
Statistical analyses
Statistical analyses were performed using PRISM 4
(Graphpad Software, San Diego, CA, USA) and JMP
software 6.0.2 (SAS Institute Inc., Cary, IL, USA). All
data derived from the animal experiment analyses are
expressed as group means ± S.E.M. Unless otherwise
stated, statistical analyses were performed using a one-
way ANOVA and a two-way ANOVA to detect possible
effects of MPTP treatment and genotype or time of
sacrifice. Statistical significance was determined at an
alpha level of 0.05.
Results
MyD88 depletion does not prevent MPTP-induced striatal
dopaminergic degeneration
Striatal dopamine and DOPAC contents were measured
in WT and MyD88-/- to evaluate the role of the
MyD88-dependent pathway in MPTP-induced striatal
dopaminergic depletion 14 days following the last
MPTP injection. WT mice subjected to the subacute
MPTP protocol had a 56.6% decrease in dopamine con-
tent (p < 0.001) as compared to the WT saline-treated
group, and MPTP-injected MyD88-/- mice showed a
similar 64.5% decrease (p < 0.001) compared to
MyD88-/- saline-treated animals (Figure 1A). Although
saline MyD88-/- expressed significantly higher striatal
basal dopamine levels as compared to saline WT mice
(20.2%; p < 0.01), they did not show exacerbated dopa-
mine depletion as compared to MPTP-treated WT.
MyD88-/- mice did not display different basal DOPAC
levels compared to WT. In addition, both MyD88-/-
and WT mice expressed identical levels of DOPAC
depletion following MPTP administration, with a 69.2%
decrease between both WT saline- and MPTP-treated
mice (p < 0.01) and MyD88-/- saline- vs. MPTP-treated
mice (p < 0.001; Figure 1B). No change was observed in
striatal dopaminergic turnover across groups (Figure
1C).
We further assessed whether the MyD88-dependent
pathway was involved in the MPTP-induced degenera-
tion of striatal dopaminergic terminals via the quantifi-
cation of DAT binding and TH protein expression.
[
125I]-RTI-121 binding levels were diminished to the
same level in MPTP-treated WT and MyD88-/- mice, as
compared to their respective saline-injected controls at
14 days following the end of the MPTP challenge
(68.1%; p < 0.001 and 65.8%; p < 0.001, respectively; Fig-
ure 2A). Analysis of DAT levels was further performed
by dividing the striatum into 4 quadrants (dorsomedial,
Figure 1 MyD88-/- mice display striatal MPTP-induced
dopaminergic depletion.( A) Striatal measurements of dopamine
levels, as performed by HPLC coupled to electrochemical detection,
showing a decrease in dopamine content in WT (p < 0.001) and
MyD88-/- (p < 0.001) MPTP-injected mice, as compared to saline-
treated WT and MyD88-/- mice. (B) Similar results were obtained for
DOPAC levels (p < 0.01 for WT and p < 0.001 for MyD88-/- vs.
saline-treated respective controls). (C) Striatal dopaminergic turnover
did not differ across groups. Statistical analyses were performed
using one-way ANOVA. **p < 0.01, ***p < 0.001.
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yielded similar results (data not shown). Comparable
results were obtained for striatal TH protein expression.
While MPTP-treated WT mice exhibited a 31.8% (p <
0.001) decrease when compared to their saline counter-
parts, a 47.8% (p < 0.001) reduction was observed
between saline treated and toxin treated MyD88-/- mice
(Figure 2B).
The absence of MyD88 does not modify MPTP-induced
nigral dopaminergic degeneration
We next examined the role of the MyD88-dependent
pathway on nigral TH+ cell bodies. No significant dopa-
minergic neuronal degeneration was observed 3 h fol-
lowing the end of the MPTP challenge, as revealed by
stereological counts of SNpc TH+ neurons (data not
shown). In contrast, WT animals, 14 days following the
MPTP challenge, had a significant reduction in dopami-
nergic cell number in the SNpc, which was of similar
magnitude between WT (20.5%; p < 0.05) and
MyD88-/- (21.5%; p < 0.05) mice when compared to
their respective saline-treated controls (Figure 3A, B). A
two-way ANOVA revealed a significant effect of the
MyD88-/- genotype in relation to the decrease in num-
ber of SN TH+ cells 14 days (p = 0.0293), but not at 3
h following the completion of the MPTP protocol (data
not shown).
Microglial response following the subacute MPTP
challenge in WT mice
The microglial response generated by the subacute
MPTP regimen employed in the present study has not
been as extensively characterized as in other MPTP
lesioning protocols [32,67]. In order to assess the micro-
glial activation during the course of MPTP injections
and neuronal degeneration in real time, we capitalized
on the TLR2-luc/gfp reporter mouse, a model in which
microglial activation/innate immune response can be
longitudinally visualized using biophotonic/biolumines-
cence imaging and high sensitivity/high resolution CCD
camera [62]. The TLR2-luc/gfp mice were thus
Figure 2 MyD88-/- mice have MPTP-induced dopaminergic
striatal terminal degeneration.( A) Striatal measurements of DAT
binding, as assessed by [
125I]-RTI-121 autoradiography, revealed a
significant decrease both in WT and MyD88-/- mice, as compared to
vehicle treated WT and MyD88-/- mice (p < 0.001). (B) Western blot
analysis of TH protein expression in the striatum further
demonstrated a loss of dopaminergic fibers in both MPTP-treated
groups (p < 0.001). Statistical analyses were performed using one-
way ANOVA. ***p < 0.001. Scale bar in A = 1 mm. Abbreviations: S:
saline-treated; M: MPTP-treated.
Figure 3 Dopaminergic neurons are not protected from MPTP
in MyD88-/- mice.( A) Stereological counts of TH+ cells in the
SNpc showed a decrease in dopaminergic neuronal count in WT
mice that received MPTP, as compared to saline-treated WT mice (p
< 0.05). MyD88-/- mice treated with MPTP were as vulnerable as
WT, displaying a similar loss of dopaminergic neurons (p < 0.05). (B)
Photomicrographs of TH immunohistochemistry staining of saline-
and MPTP-treated animals at the level of SNpc. Statistical analyses
were performed using one-way ANOVA. *p < 0.05, ***p < 0.001.
Scale bar in B = 300 μm.
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glial activation/induction of the TLR2 signal was quanti-
fied over time using in vivo imaging. A significant 1.9-
fold increase in the TLR2 signal was observed following
the third MPTP injection (p < 0.01) as compared to sal-
ine-treated controls, a response that returned to control
values from the fourth injection onwards (Figure 4A, B).
A subgroup of WT mice was sacrificed at 24 h, 7 and
14 days following the end of toxin administration.
Stereological counts of iba1+ microglia in the SNpc
revealed that, while MPTP-treated animals had a ten-
dency towards increased iba1+ cell density in the SNpc
at 24 h compared to saline-controls sacrificed at the
same time (15.0%; p = 0.1), they had a significant
Figure 4 Glial response in the subacute MPTP animal model and in MyD88-/- mice.( A) Real-time imaging of the TLR2 response during the
course of MPTP injections and 14 days following the last injection. Representative photographs of a saline- and an MPTP-treated mouse across
time, showing significant brain TLR2 signal following the third MPTP injection, as compared to saline. The data is illustrated using pseudocolor
images representing light intensity as indicated by the color scale, which were superimposed over gray-scale reference photographs. (B) (Left
graph) Quantification of the total photon emission in the brain of saline- and MPTP-treated TLR2-luc/gfp mice at each time point assessed.
(Right graph) Quantification of the areas under the curves in the two groups of animals. Statistical analyses were performed using student’s t-
tests. (C) Stereological count of iba1+ cells in the SNpc revealed a trend towards increased microglial expression in MPTP-treated mice 24 h
following the last injection, which was significantly different from saline-treated animals at 7 (p < 0.05) and 14 days (p < 0.01), and from MPTP-
treated mice at 14 days following the end of treatment (p < 0.05). (D) Photomicrograph of iba1 immunofluorescence staining of saline- and
MPTP-treated animals at the level of SNpc, which has been outlined with a solid line. (E) 3 h following the last MPTP injection, similar microglial
counts in the SNpc were seen in both saline- and MPTP-injected WT and MyD88-/- mice. (F) Western blot analysis of striatal GFAP protein levels
revealed a strong increase in the MPTP-treated mice 24 h following the last injection, which had declined significantly 14 days following the end
of treatment (p < 0.01) but still remained significantly increased compared to saline-controls at the 7-(p < 0.05) and 14-day time point (p < 0.05).
(G) MPTP treatment induced a significant increase in GFAP striatal expression of similar magnitude in both WT (p < 0.01) and MyD88-/- mice (p
< 0.001). Statistical analyses were performed using one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001 in comparison to saline-controls;
##p<
0.01 in comparison to MPTP-treated mice sacrificed at 24 h. Scale bar in D = 150 μm. Abbreviation: AUC: areas under curves; SNpc: substantia
nigra pars compacta; SNr: substantia nigra reticulata; VTA: ventral tegmental area; WT: wild type.
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Page 7 of 12increase in comparison to saline-controls at 7 (25.0%; p
< 0.05) and 14 days (31.8%; p < 0.01) and MPTP-treated
mice at 14 days (28.7%; p < 0.05). Two-way ANOVA
revealed a significant effect of the time of sacrifice on
microglial density (p = 0.0007), which confirms a reduc-
tion of iba1+ cell density across time in both saline and
MPTP treated animals (Figure 4C, D). We subsequently
assessed whether this slight increase in microglial den-
sity could be present at 3 h following the end of MPTP
treatment. In WT and MyD88-/- mice sacrificed at 3 h,
however, no change in microglial density was observed
(Figure 4E), but an effect of MPTP treatment was
revealed by a two-way ANOVA indicating a diminished
iba1+ cell density in MPTP-treated groups.
Astrocytic response following the subacute MPTP
challenge
In the acute MPTP model, the astrocytic response has
also been reported to play an important role in the
events leading to dopaminergic degeneration [68], a
response which seemingly occurs following microgliosis
[67]. We thus investigated the astrocytic response at 24
h, 7 and 14 days following the completion of the MPTP
challenge. Striatal GFAP protein quantification revealed
substantially elevated levels at the three time points ana-
lyzed (24 h, 7 days and 14 days following the end of
MPTP treatment) in comparison to saline-controls
sacrificed at the same time (68.5%: p < 0.001; 40.7%; p <
0.05; 47.1%; p < 0.05, compared to their saline-controls,
respectively) (Figure 4F). Elevated GFAP levels detected
in MPTP groups was time-dependent, as the groups
sacrificed at 7 and 14 days had significantly decreased
levels at these times as compared to MPTP treated ani-
mals sacrificed 24 h following the end of treatment (p <
0 . 0 1 )( F i g u r e4 F ) .G i v e nt h ep r e s e n c eo fap e r s i s t e n t
astrocytic response in the subacute model of MPTP, we
next investigated the role of MyD88 in the astrocytic
response at 14 days following the completion of MPTP
challenge. At this time point, MPTP-treated WT mice
displayed a 36.1% increase (p < 0.01) in GFAP protein
levels in the striatum as compared to WT saline-treated
mice (Figure 4G). Similarly, MyD88-/- mice adminis-
tered MPTP had a 48.5% (p < 0.001) increase in GFAP
p r o t e i ne x p r e s s i o na sc o m p a red to MyD88-/- controls.
In contrast, western blot analysis of GFAP levels in the
mesencephalon did not reveal increased GFAP protein
expression at this time of sacrifice (data not shown).
Thus we have shown that there is an equivalent striatal
astrocytic response in MPTP treated animals regardless
of whether they express MyD88.
Discussion
Our results indicate that mice lacking the adaptor pro-
tein MyD88, an important element of the innate
immune response, are not protected against the degen-
eration of the dopaminergic nigrostriatal pathway
induced by the subacute administration of MPTP.
This result is of particular interest given that we have
recently demonstrated that the dopaminergic neuronal
toxicity induced by the same regime of MPTP adminis-
tration in the myenteric plexus of the ENS was pre-
vented by the absence of the MyD88-dependent
pathway in this same cohort of animals [55]. The pro-
tective effect of MyD88 deletion was further linked to a
switch in immunophenotype of the infiltrating macro-
phages from “M1” to “M2”.I n d e e d ,w h i l e“M1” polar-
ized macrophages adopt pro-inflammatory functions,
“M2” polarized macrophages coordinate tissue repair
and remodeling, as well as immunoregulation [69]. This
suggests that the MyD88-dependent pathway is impli-
cated in the immunophenotype fate of macrophages
contributing to the ENS inflammatory response induced
by MPTP, in particular triggering the tissue repair func-
t i o n so ft h i sc e l lt y p e( s e eF i g u r e5 )[ 5 5 ] .B a s e do nt h e
results obtained in the ENS using the subacute MPTP
mouse model, we hypothesized that this pathway would
have a similar role to play in dopaminergic neuronal
d e g e n e r a t i o ni nt h eC N S .U s i n gt h es a m ec o h o r to f
lesioned mice, though, we failed to show an involvement
of this pathway in the brain, at least within the nigros-
triatal pathway. An obvious explanation for this differ-
ence in the role played by MyD88 in these two systems
relates to the absence of a blood-brain-barrier in the
gut, which potentially facilitates macrophage infiltration.
In the CNS, however, the infiltration of macrophages
has been observed in the acute MPTP mouse model of
PD [70]. Differences in receptor expression between
microglia and peripheral macrophages could also
account for the absence of any effect of MyD88 in the
CNS MPTP lesion. Although peripheral macrophages
outside the CNS interact with other immune cells, such
as T and B lymphocytes, microglia preferably interact
with other CNS cells and this may be an important
determinant as to the way in which MyD88 pathways
cause neuronal cell loss [71,72]. Regardless, the contrast-
ing role of the MyD88-dependent pathway in the ENS
vs. the CNS raises the possibility that the pathophysiol-
ogy of dopaminergic degeneration may be different from
site to site, further suggesting that the use of anti-
inflammatory agents targeting a specific pathway may
not impact on neuronal losses found in PD.
Since the activation of microglia has been reported by
various groups to be essential for MPTP-induced dopa-
minergic degeneration in the acute MPTP mouse model
of PD [31,32,35], we assessed the extent of microgliosis
at different time points during and following the end of
MPTP treatment. Neuroinflammatory-induced micro-
glial activation has been associated with a strong
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Page 8 of 12induction of several TLRs [45,73]. Despite low levels of
TLR2 in the mouse brain in basal condition, it is
strongly induced in microglia following infection or
brain injury [62]. We therefore used bioluminescence
imaging of the TLR2 response to evaluate in vivo the
time course of the microglial response in our subacute
MPTP model. Our results demonstrate an early and
transient microglial response following the third MPTP
injection, confirming that the MPTP regimen used in
our study provides an adequate setting to study the
MyD88-dependent pathway.
In accordance with the results obtained using biolumi-
nescence imaging, no significant difference of microglial
density was observed between the MPTP- and saline
treated groups at any time point of sacrifice assessed fol-
lowing the end of MPTP treatment, although there was
a significant decrease with time in both groups. This
suggests that the MPTP mouse model utilized in this
study is characterized by a much weaker microglial
response, peaking at the 3
rd MPTP injection. MPTP-
induced microglial activation has indeed been demon-
strated to vary according to the regime employed. More
specifically, it has been reported that acute MPTP injec-
tions (4 injections in 1 day) consistently induces micro-
glial activation, whereas a more subchronic/subacute
approach (1 injection per day for 5 consecutive days)
triggers a significantly weaker response [74], similar to
our observations using a 7 injection regime over 5-days
of administration. This may help explain some of the
discrepancies in the mechanisms leading to cell death
outlined in the acute and subacute MPTP animal mod-
els. The acute model necessitates microglial activation
while the subacute model is less dependent on this and
relies for its toxic effects through the activation of
Figure 5 Schematic drawing of the different role for MyD88 in the loss of dopaminergic neurons in the ENS vs. CNS following
subacute MPTP challenge. In the ENS, MPTP induces an immune response characterized by neutrophile and monocyte infiltration, and by a
pro-inflammatory immunophenotype of resident macrophages. This immune response is accompanied by dopaminergic neuronal death.
Depletion of MyD88 prevents macrophage infiltration and in fact promotes a shift to pro-repair immunophenotype in monocyte population of
the ENS in response to MPTP. This favorably impacts the survival of the dopaminergic neurons in the myenteric plexus. In the brain of the same
mice, however, dopaminergic neurons of the substantia nigra, along with striatal terminals, undergo degeneration/depletion when exposed to
MPTP. These contrasting findings may relate to the type and intensity of the inflammatory responses provoked by MPTP in the two nervous
systems. Another likely scenario relates to the BBB. Unlike in the ENS [55], cell infiltration from the blood to the brain may not occur following a
subacute MPTP challenge. Abbreviation: SN: substantia nigra.
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Page 9 of 12molecules involved in the mitochondrial apoptotic cas-
cade [75,76], such as caspase-11 [74], which also contri-
butes to IL-1b secretion [77].
As mentioned above, several inflammatory pathways
have already been shown to substantially contribute to
acute MPTP-induced nigrostriatal degeneration, and
include NFB activation in astrocytes [78]. Based on our
results, we cannot exclude the involvement of NFBi n
MPTP-induced dopaminergic degeneration in the CNS,
since while NFB can be recruited by the MyD88-
dependent pathway to produce pro-inflammatory cyto-
kines [79], it can also be activated by MyD88-indepen-
dent pathways.
In addition to the MPTP mouse model of PD, inflam-
mation has been identified as a key player in other mod-
els using different toxins such as 6-OHDA and LPS.
However, the stereotaxic disruption of the blood-brain
barrier to generate both models allows for the infiltra-
tion of peripheral immune cells, an event for which the
MyD88-dependent pathway has previously been identi-
fied to play a role in the MPTP-induced dopaminergic
degeneration in the ENS [55]. In addition, while LPS, a
TLR4 ligand, provides a suitable model to study the
effects of activated microglia on a degenerating system
(e.g. dopamine), it would not have been suitable for our
study, given that MyD88-/- mice are unresponsive to
the toxin [60].
Despite increased mRNA levels of TLR4, TLR9 and
MyD88 in mice acutely treated with MPTP [53], our
results do not suggest a fundamental role for the
MyD88-dependent pathway in MPTP-induced dopami-
nergic degeneration, at least not in the CNS in the con-
text when the toxin is administered subacutely. Because
apoptosis is likely to play an important role in degener-
ating processes of the SNpc in the subacute MPTP
model of PD used here, cellular-debris-derived damage
associated molecular pattern molecules (DAMPs), as the
result of cell death, could have generated a secondary
inflammatory response driven by the MyD88-dependent
pathway, creating additional dopaminergic death as
observed, for example, in stroke models [80]. Our
results, however, do not support this hypothesis, as no
significant difference in the magnitude of CNS-related
degeneration was seen between MPTP-treated WT and
MyD88-/- mice.
Conclusions
Our study provides important insights into the contribu-
tion of a paramount pathway of the innate immune sys-
tem in mediating dopaminergic cell loss in the CNS in
response to subchronic MPTP lesions. We have shown
that while MyD88 is essential in the MPTP-induced
dopaminergic cell death in the ENS, the nigrostriatal
dopaminergic degeneration seen in the subacute MPTP
mouse model of PD is MyD88-independent. These
results highlight the dichotomy in the role of the
MyD88-dependent pathway in the central vs. enteric
nervous system. This sheds light onto the role of the
inflammatory response as a whole to the pathophysiol-
ogy of PD. Taken together, these findings have impor-
tant implications for the development of novel
therapeutic strategies to treat all aspects of PD.
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